PT  - JOURNAL ARTICLE
AU  - Mehta, G
AU  - Lin, S
AU  - Nadar, A
AU  - Bharadwaj, PV
AU  - Kumar, R
AU  - Balaji, A
AU  - Macdonald, S
AU  - Sheikh, M
AU  - Saeidinejad, MM
AU  - Sharma, SR
AU  - King, JJ
AU  - Mookerjee, RP
AU  - McDonagh, L
AU  - Afuwape, SA
AU  - Moore, K
AU  - Jalan, R
TI  - Development and Clinical Evaluation of AlcoChange: a Digital Therapeutic for Patients with Alcohol-Related Liver Disease
AID  - 10.1101/2023.08.22.23293936
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.08.22.23293936
4099  - http://medrxiv.org/content/early/2023/08/22/2023.08.22.23293936.short
4100  - http://medrxiv.org/content/early/2023/08/22/2023.08.22.23293936.full
AB  - Background and aims Maintenance of abstinence in alcohol-related liver disease (ARLD) is a major unmet therapeutic need. Digital therapeutics can deliver ongoing behavioural therapy, in real-time, for chronic conditions. The aim of this project was to develop and clinically test AlcoChange, a novel digital therapeutic for ARLD.Methods AlcoChange was developed using validated behaviour change techniques (BCTs) and a digital alcohol breathalyser. This was an open-label, single-centre study. Patients with ARLD, ongoing alcohol use (within 1 month) and possession of a suitable smartphone were eligible. Patients were recruited from inpatient and outpatient settings, and received AlcoChange therapy for 3-months. The primary outcome was reduction in alcohol use from baseline to 3-months, measured by timeline follow-back (TLFB). Secondary outcomes included: (i) compliance with the AlcoChange app, (ii) alcohol-related and all-cause hospital re-admissions up to 1-year, (iii) qualitative analysis to determine factors associated with compliance.Results Sixty-five patients were recruited, of whom forty-one completed the study per-protocol. Patients compliant with the intervention (>60 logins over 3-months) had a significant reduction in alcohol use from baseline compared to non-compliant patients [median (IQR): −100% (100% to −55.1%) vs −57.1% (−95.3% to +32.13%), p=0.029]. The proportion attaining abstinence at 3-months was higher in the compliant group (57.1% vs 22.2%, p=0.025). The compliant group had a significantly decreased risk of subsequent alcohol-related re-admission up to 12-months (p=0.008). Qualitative analysis demonstrated receiving in-app feedback and presence of health-related ‘sentinel event’ were predictors of compliance with the intervention.Conclusions Use of the novel digital therapeutic, AlcoChange, was associated with a significant reduction in alcohol use and increase in proportion attaining abstinence in ARLD patients. Definitive, randomized trials are warranted for this intervention.Competing Interest StatementRJ is the founder of Cyberliver Ltd, the company that holds the intellectual property for AlcoChange. He is also the founder of Yaqrit Discovery and Hepyx Limited, and inventor of OPA (patented by UCL and licensed to Mallinckrodt Pharma). BPV, RK, AB are employees of Cyberliver Ltd. GM is a co-founder of Hepyx Ltd.Clinical TrialClinicalTrials.gov Identifier: NCT03474328Funding StatementThis study was supported by a grant from The Health Foundation (Grant ref: 1943)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the UK Health Research Authority (HRA) Research Ethics Committee (REC 16/SW/0035); protocol attached in Supplementary material).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors